Global Adalimumab, Infliximab and Etanercept Biosimilars Market

The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease. Biosimilar monoclonal antibodies are highly similar to actual monoclonal antibodies in terms of pharmaceutical quality, safety, and efficacy, and are used to boost immunity by identifying and neutralizing foreign bodies. The market consists of revenue generated by the biosimilar monoclonal antibodies companies by the sales of these products. The biosimilar monoclonal antibodies market covered in this report is segmented by type into synthetic chemicals, biopharmaceuticals, others and by application into chronic & autoimmune diseases, oncology, others. The global biosimilar monoclonal antibodies market is expected to grow from $3.52 billion in 2020 to $4.33 billion in 2021 at a compound annual growth rate (CAGR) of 23%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar monoclonal antibodies market is expected to reach $10.92 billion in 2025 at a CAGR of 26%. The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune disease, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. According to the American cancer society (ACS), in 2020, about 1.8 million new cancer cases are expected in the United States. Therefore, the prevalence of chronic diseases including cancer is expected to drive the biosimilar monoclonal antibodies market. Stringent regulations imposed on approvals of biosimilars is anticipated to hinder the growth of the biosimilar monoclonal antibodies market. The governments of different regions impose different rules regarding the production and use of biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars, only 7 biosimilars including 4 originating biologics could enter the US commercial market. The strict government policies for approval of these drugs negatively impact manufacturers in the biosimilar monoclonal antibodies market. The focus areas for many companies in the biosimilar monoclonal antibodies market has shifted to mergers and acquisitions to acquire more production capabilities. Large prime manufactures are forming joint ventures or buying small or midsized companies to acquire new capabilities, or to gain access to new markets. In February 2017, Aurobindo Pharma Limited announced that it had acquired four cell culture-derived biosimilar products from TL Biopharmaceutical AG of Switzerland. As part of the agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally. Out of the four biosimilars acquired, three of them are monoclonal antibodies in oncology. In another instance, in May 2020, AbbVie, a US-based biopharmaceutical company, announced its decision to acquire Allergan for an amount of $63 million. This transaction expands and diversifies AbbVie's revenue base and supports in maintaining its leadership positions in biosimilar monoclonal antibodies In May 2020, AbbVie, a US-based biopharmaceutical company, has acquired Allergan for an amount of $63 million. This transaction expands and diversifies AbbVie's revenue base and supports in maintaining its leadership positions in biosimilar monoclonal antibodies. Allergan is an Ireland-based pharmaceutical company that manufactures, develops, and markets drugs, biosimilars, medical devices, eye care, and others. Major players in the biosimilar monoclonal antibodies market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, and Intas Pharmaceuticals Limited. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilar monoclonal antibodies market is segmented - 1) By Type: Synthetic Chemicals, Biopharmaceuticals, Others 2) By Application: Chronic & Autoimmune Diseases, Oncology, Others 3) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab

The biosimilar therapeutic peptides market consists of sales of biosimilar therapeutic peptides by the companies that are engaged in developing and commercialization of biosimilar peptides drugs for therapeutic applications. Peptide drugs are used as replacement therapies which supplements peptide hormones when the endogenous levels tend to decrease. Biosimilar therapeutic peptides find its application in the treatment of cardiovascular diseases, metabolic diseases, respiratory conditions, cancer, and respiratory diseases. The biosimilar therapeutic peptides market covered in this report is segmented by route of administration into parenteral route, transdermal route, others and by application into cancer, cardiovascular, central nervous systems, metabolic disorders, infection, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders. The global biosimilar therapeutic peptides market is expected to grow from $0.76 billion in 2020 to $0.87 billion in 2021 at a compound annual growth rate (CAGR) of 14.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar therapeutic peptides market is expected to reach $2.25 billion in 2025 at a CAGR of 27%. The increasing aging population is projected to surge the patients with chronic diseases contributing to the biosimilar therapeutic peptides’ market growth. Elderly people are more prone to various chronic diseases, surging the old age population rapidly across the world and is predicted to continue over the forecast period. According to the World Health Organization (WHO), the world’s population over the age of 60 years is expected to reach 2 billion by the end of 2050, up from 900 million in 2015. In 2018, approximately 125 million people were aged over 80 years or older. Moreover, according to the World Population Prospects: the 2019 Revision, the number of people aged 80 years and above is likely to increase from 143 million in 2019 to 426 million in 2050. Biosimilar therapeutic peptides are used for the treatment of various chronic diseases and cancer. The expected increase in the aging population suffering from various chronic conditions will drive the biosimilar market. The long and costly drug approval process is expected to limit the growth of the biosimilar therapeutic peptides market over the upcoming years. The development, approval, and launch of new drugs is an expensive and prolonged procedure that includes expensive research stages. A new drug has to go through four phases of clinical trials and screening by the regulatory body including Food and Drug Administration (FDA) (USA), Medicines and Healthcare Products Regulatory Agency (MHRA) (UK), and Medicines and Healthcare Products Regulatory Agency (MHRA) (India). According to a report of Tufts Center for the Study of Drug Development published by the Journal of Health Economics in 2019, a cost to develop new drugs is $2.6 billion whereas the approval rate for drugs entering clinical trail is less than 12%. Therefore, long and costly drug approvals of new drug candidates are anticipated to hinder the growth of biosimilar therapeutic peptides market. During the historic period, biosimilar therapeutic peptides market witnessed a growth in research collaborations as well as research funding approvals. Key companies are focusing on collaborations with companies and organizations to enhance their research & developments, expand their product portfolio, and geographical reach. For instance, in January 2020, a UK-based biotechnology company focusing on developing a class of therapeutics based on its proprietary bicyclic peptide technology announced a collaboration with Cancer Research UK to develop BT7401, a new bicycle immune-oncology candidate. Cancer Research UK will fund and sponsor the development of a new candidate. In addition to this, in April 2018, Sapience Therapeutics, Inc., a USA-based biotechnology company focused on research & development on peptide therapeutics announced a research collaboration with the University of Bath (UK) to develop and discover new therapeutic agents for oncology applications. Hence, research collaborations to develop new therapeutic peptides is a major trend in the market. In October 2019, Zealand Pharma A/S, a Denmark-based biotechnology company specializing in the discovery and development of innovative peptide-based medicines acquired Encycle Therapeutics, Inc. for up to $80 million. The acquisition is expected to strengthen the Zealand Pharma A/S in the peptide therapeutics and in targeting gastrointestinal diseases with the addition of orally delivered preclinical macrocycle peptide. Encycle Therapeutics, Inc., is a Canada-based biotechnology company specializing in unique platform technology that allows the synthesis of macrocyclic peptides demonstrating improved drug-like properties. Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S. The regions covered in the biosimilar therapeutic peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilar therapeutic peptides market is segmented - 1) By Route Of Administration: Parenteral Route, Transdermal Route, Others 2) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders 3) By Type: Innovative, Generic

The rituximab biosimilars market consists of sales of rituximab biosimilars. Biosimilars are pharmaceuticals that are manufactured using cell lines and are similar to biologics. Rituximab biosimilars are used as a single agent or in combination with chemotherapy for the treatment of various diseases including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), microscopic polyangiitis (MPA), and granulomatosis with polyangiitis (GPA). The rituximab biosimilar market covered in this report is segmented by application into non-hodgkin’s lymphoma, chronic lymhocytic leukemia, rheumatoid arthritis, others and by hospital pharmacy into hospital pharmacy, online pharmacy, retail pharmacy, other direct distribution channels. The global rituximab biosimilars market is expected to grow from $1.75 billion in 2020 to $1.9 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The rituximab biosimilars market is expected to reach $3.02 billion in 2025 at a CAGR of 12%. The rising prevalence of non-Hodgkin's lymphoma (NHL) is predicted to contribute to the growth of the rituximab biosimilars market. Non-Hodgkin's lymphoma or lymphoma is cancer that starts in white blood cells, lymphocytes that are part of the body’s immune system. In 2018, rituximab-abbs was approved as the first rituximab biosimilars for the treatment of patients with B-cell non-Hodgkin lymphoma (NHL) and adult patients with CD20-positive. According to the National Library of Medicine statistics, non-Hodgkin lymphoma (NHL) was ranked as 5th to 9th most common cancers in most of the countries globally, with approximately 5,10,000 new cases in 2018, globally. Moreover, according to the American Cancer Society’s, NHL is the most common cancers in the USA accounting for about 4% of all cancers. About 77,240 people (34,860 females and 42,380 males) are estimated to be diagnosed with NHL by the end of 2020 in the USA. Thus, growing cases of non-Hodgkin's lymphoma is predicted to generate high demand for rituximab biosimilars over the forecast period. The high cost associated with rituximab biosimilars acts as a major restraint for the growth of rituximab’s market over the upcoming years. The cost of the subcutaneous option was costlier than IV biosimilar rituximab. The cost of subcutaneous formulation for patients with small body size is between $3,805 and $8,807 and for medium body size between $325 to $6109 and $484 to $6267 for 2 infusion speeds. The high costs of rituximab biosimilars makes it unaffordable for treatment of patients with low income, hindering the growth of the market. The companies operating in the biosimilars are continuously focusing on new product development in collaborations with other companies operating in the industry. Innovations through partnerships is shaping the rituximab biosimilars market. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd together announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche's Rituxan (rituximab) available in the USA for the treatment of rheumatoid arthritis. Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA, and Intas Biopharmaceuticals Ltd. The regions covered in the rituximab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global rituximab biosimilars market is segmented - 1) By Application: Non-Hodgkin's Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis, Others 2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels 3) By Route Of Administration: Subcutaneous, Intravenous, Molecular Type

The biosimilar hormones market consists of sales of biosimilar hormones by entities that engage in manufacturing biosimilar hormones. These hormones are used when patients have a drop in hormones in their bodies or are unbalanced. Only goods and services traded between entities or sold to end consumers are included. The biosimilar hormones market covered in this report is segmented by type into teriparatide biosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars, others and by application into research & biotechnology, diagnostics, biocatalysts, therapeutics, others. The global biosimilar hormones market is expected to grow from $1.94 billion in 2020 to $2.19 billion in 2021 at a compound annual growth rate (CAGR) of 12.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar hormones market is expected to reach $5.35 billion in 2025 at a CAGR of 25%. The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions are evolving over the years and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market. For instance, according to the Italian Journal of Pediatrics, the prevalence of growth hormone deficiency (GHD) in childhood widely varies between 1 out of 3480 and 1 out of 30,000 children annually. In children, the growth hormone can influence bone mineralization and lead to several metabolic effects, including glucose and lipid homeostasis. Annually, about 6,000 adults are diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the biosimilar hormones market. Stringent regulations imposed on the approval of hormone biosimilars limits the growth of the biosimilar hormones market. Biosimilars are approved on the same standard of pharmaceutical quality, efficacy, and safety that apply to all biologics approved in the European Union. There should be a similarity between the biologics and biosimilars, and as the process of manufacturing differs, the approval process becomes expensive and likely hinders the growth of the biosimilar hormones market. Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launch in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products across various locations to boost sales and maximize profits. For instance, in October 2019, Biocon Biologics and Mylan N.V. announced the launch of biosimilar hormones in Australia to treat the polygenic disorder. In March 2018, BRAIN AG, a technology company in the field of industrial biotechnology, developing microorganisms, natural substances and enzymes for industrial use, acquired Biocatalysts for an undisclosed amount. The strategic acquisition of a majority stake in Biocatalysts is intended to accelerate product-driven growth in the fast-growing specialty enzyme market and broaden the portfolio of the enzyme business of BRAIN. Biocatalysts is a US-based biotechnology company focused on the development, production and distribution of specialty enzymes for various industries such as food and fine chemicals. Major players in the biosimilar hormones market are Teva Pharmaceutical, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma. The regions covered in the biosimilar hormones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilar hormones market is segmented - 1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Others 2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Others 3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Speciality Clinics

The biosimilar lymphocyte modulator market consists of sales of immune regulating lymphocyte modulators by entities (organizations, sole traders and partnerships) that manufacture lymphocyte modulator biosimilars. Lymphocyte modulators are intended as an aid in the treatment for cancer and autoimmune diseases, and for regulating carotene intake in humans with a weak immune system. Only goods and services traded between entities or sold to end consumers are included. The biosimilar lymphocyte modulator market covered in the report is segmented by drug into campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar, anti-CD38 daratumumab biosimilar, anti-CS1 elotuzumab biosimilar and by disease into arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, others. The global biosimilar lymphocyte modulator market is expected to grow from $1.22 billion in 2020 to $1.31 billion in 2021 at a compound annual growth rate (CAGR) of 7.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar lymphocyte modulator market is expected to reach $1.91 billion in 2025 at a CAGR of 10%. Immunotherapy combined with other cancer treatments is expected to drive the growth of the biosimilar lymphocyte modulators market. The combination of immunotherapies or pairing of immunotherapies with other types of cancer treatments such as chemotherapy or radiation enhances the benefit associated with lymphocyte modulators. According to a study conducted by the researchers at Washington University School of Medicine in St. Louis, combining two immunotherapy strategies into one can give better results for certain blood cancers such as leukaemia. Evidence suggests that this new approach could be safer with reduced side effects than other cellular immunotherapies such as CAR-T cell. The combination approach, therefore, saves patients’ life from a life-threatening reaction of the immune system thereby driving the growth of the lymphocyte modulator market. The shortage of raw material for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market. Drug shortages are due to several factors including challenges for acquiring raw materials, manufacturing problems, regulatory issues, business decisions, and numerous disturbances within the supply chain. They adversely affect patient care by causing the replacement of safe and effective therapies with elective medicines, compromising or delaying medical procedures, or causing medication errors. For instance, in January 2019, the American Society of Haematology, an association comprising of clinical scientists and physicians that provides care to patients in diverse settings, sent a letter to USFDA highlighting the issue of shortage of critical hematologic drugs such as etoposide and methotrexate, which have no alternatives. Mainly the drug etoposide, which is a chemotherapeutic drug, that is a crucial component in treatment regimens designed to be curative for life-threatening conditions including leukaemia and lymphomas. Due to the shortage, some patients have received less effective treatment. Thus, the raw material shortages cause delayed and compromised medical treatments and also results in limiting the growth of the market. Tumor-Infiltrating Lymphocyte Immunotherapy has been gaining popularity in recent times because of its positive results in anti-cancer treatments. Tumor-infiltrating lymphocytes (TILs) comprise of all lymphocytic cell populaces that have occupied the tumor tissue. TILs have been depicted in various solid tumors including breast cancer, and are emerging as a significant biomarker in predicting the efficacy and result of treatment. Due to promising results, many companies have started launching TIL technologies. For instance, in January 2020, Lovance Biotherapeutics, a US-based start-up company, has licensed TALEN technology from Cellectis to develop gene-editing tumor-infiltrating lymphocytes (TIL) to treat several cancer indications. Other companies investing in TIL technology are Optera Therapeutics Corp and TILT Biotherapeutics. In July 2020, Cytocom, Inc., a US-based immunotherapy generating company, announced the acquisition with ImQuest Life Sciences, Inc. for an undisclosed sum. The deal is expected to support Cytocom’s vision of strategic growth and strengthen internal drug development programs with new assets and secured revenue-generating operations, scientific resources, and tools and capacity. ImQuest Life Sciences is a US-based company with leading drug discovery and development. The company was founded in 2004. Major players in the biosimilar lymphocyte modulator market are Pfizer, Biogen, Genentech, Novartis, and Celltrion. The regions covered in the biosimilar lymphocyte modulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar lymphocyte modulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilar lymphocyte modulator market is segmented - 1) By Drug: Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar 2) By Disease: Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis, Others

The biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer. Biosimilars are pharmaceuticals that are manufactured using cell lines and offer no clinical difference as compared to biologics. Biosimilars are made once the patent of biologics is expired. The biosimilars market covered in this report is segmented by product into recombinant non-glycosylated proteins, recombinant glycosylated proteins. The biosimilars market is also segmented by types into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, others and by application into oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, others. The global biosimilars market is expected to grow from $7.49 billion in 2020 to $8.05 billion in 2021 at a compound annual growth rate (CAGR) of 7.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilars market is expected to reach $21.13 billion in 2025 at a CAGR of 27%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market. The lack of awareness about biosimilars among primary care physicians (PCPs) and specialists limits the growth of the biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, lack of familiarity with biosimilars reduces the likelihood of prescribing the drugs to patients which affects the demand for new biosimilars in the market. For instance, in 2018, according to the PwC’s Health Research Institute, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns included safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the biosimilars market. Production of new insulin biosimilars is trending in the biosimilars market. The key players operating in the biosimilars market are investing in creating a biosimilar of insulin. This is also promoting competition among various biosimilar manufacturers. For instance, in 2019, Mylan, a U.S-based pharmaceutical company, in partnership with Biocon, an Indian based biopharmaceutical company launched biosimilar insulin glargine named Semglee. Also, in 2019, Oramed Pharmaceuticals, a Jerusalem based pharmaceutical company developed an oral insulin drug named ORMD-0801 to treat type 2 diabetes. Thus, companies in the biosimilars market are investing in the development of insulin biosimilar to gain profits. In June 2018, Japan-based Fuji Pharma Co., Ltd. acquired a 4.2% stake of Alvotech for US$50 million. The acquisition involves Alvotech to develop, manufacture and supply biosimilars and Fuji Pharma will sell the biosimilars in Japan. Alvotech is an Iceland-based biopharmaceutical company. Major players in the biosimilars market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, and STADA Arzneimittel. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilars market is segmented - 1) By Product: Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins 2) By Types: Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Others 3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Others

Filgrastim Biosimilars Market Definition

The filgrastim biosimilars market consists of sales of filgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that manufacture filgrastim biosimilars. Filgrastim biosimilar treatment is used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment. The drugs may also be used to increase the number of hematopoietic stem cells in the blood before collection for use in hematopoietic stem cell transplantation. Filgrastim treatment may also be used for treating other diseases such as chronic and autoimmune diseases, growth hormone deficiency and infectious diseases.

Pegfilgrastim Biosimilars Market Definition

The pegfilgrastim biosimilars market consists of sales of pegfilgrastim biosimilar drugs and related services. The drugs are used during the course of cancer treatment in order to reduce the infection risk for those patients undergoing immunosuppressant treatments, such as chemotherapy. The drug has further applications where protection from infections where immune system is compromised, such as in bone marrow transplants. Biosimilars are biological products which are being produced to be identical to a biologic already approved, known as reference drugs. Biosimilars should have similar safety and efficacy compared to the reference biologic product. Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue filgrastim.